Tests a herbal powder added to inhaled medicine for allergic asthma
Tests a traditional Chinese herbal powder with inhaled medicine in adults with allergic asthma.
Plain-language title generated from the registry record
Registry title: Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome
Key facts
- Where
- Hangzhou, Jinan, and Zhengzhou, ChinaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07352488, who can take part
Where in China
- Hangzhou Third People's HospitalHangzhou, ChinaNo longer taking part
- Affiliated Hospital of Shandong University of Traditional Chinese MedicineJinan, ChinaNo longer taking part
- The First Affiliated Hospital of Henan University of Chinese MedicineZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Henan University of Traditional Chinese Medicine
- Trial code
- NCT07352488
- Record updated
- 20 January 2026
- Original description
Allergic asthma is a common allergic disease characterized by a protracted disease course and recurrent episodes, which severely impairs patients' physical and mental health. There is a paucity of high-quality clinical evidence in the treatment of allergic asthma with traditional Chinese medicine (TCM). This study will enroll patients who are persistent allergic asthma with spleen deficiency and dampness accumulation syndrome. A multicenter, randomized, double-blind, placebo-controlled trial design is adopted. The experimental group will receive Modified Shenling Baizhu Powder in addition to Budesonide and Formoterol Fumarate Powder for Inhalation, while the control group will receive a placebo in addition to the same inhalation therapy. Both groups will undergo an 8 week of treatment followed by a 12 week of follow-up. The primary outcome is Asthma Control Test scores, and the secondary outcomes include acute exacerbations, Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, pulmonary function, airway inflammatory markers, clinical symptom scores, serum inflammatory markers, immune markers, and use of controller medications.Read full original descriptionShow less
Effect of Modified Shenling Baizhu Powder on Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome: A Multicenter, Randomized Controlled Trial
Allergic asthma is a common allergic disease characterized by a protracted disease course and recurrent episodes, which severely impairs patients' physical and mental health. There is a paucity of high-quality clinical evidence in the treatment of allergic asthma with traditional Chinese medicine (TCM). This study will enroll patients who are persistent allergic asthma with spleen deficiency and dampness accumulation syndrome. A multicenter, randomized, double-blind, placebo-controlled trial design is adopted. The experimental group will receive Modified Shenling Baizhu Powder in addition to Budesonide and Formoterol Fumarate Powder for Inhalation, while the control group will receive a placebo in addition to the same inhalation therapy. Both groups will undergo an 8 week of treatment followed by a 12 week of follow-up. The primary outcome is Asthma Control Test scores, and the secondary outcomes include acute exacerbations, Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, pulmonary function, airway inflammatory markers, clinical symptom scores, serum inflammatory markers, immune markers, and use of controller medications.
Inclusion: Patients who are persistent allergic asthma; Patients who meet the diagnostic criteria for the spleen deficiency and dampness accumulation syndrome; Patients who are aged between 18 and 80 years; Patients who voluntarily accept the treatment and sign the informed consent form.
Exclusion: Patients who participated in another clinical trial within one month prior to enrollment; Patients who have chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis , active pulmonary tuberculosis, or pulmonary embolism, etc; Patients who have severe cardiovascular or cerebrovascular diseases; Patients who have severe liver or kidney diseases; Patients who have a history of tumor; Patients who have cognitive impairment or psychiatric disorders; Patients who are allergic to medication(s) used; Patients who are pregnant or breastfeeding.